Neurological treatments and biotech research by Amylyx Pharmaceuticals

  • Elena Nikulina
  • 24.03.2026
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH
Amylyx Pharmaceuticals announced the completion of patient enrollment for its pivotal Phase 3 LUCIDITY clinical trial targeting post-bariatric hypoglycemia (PBH). The company expressed gratitude ...
  • Igor Krasulya
  • 17.03.2026
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges
Amylyx Pharmaceuticals has announced a new hiring initiative, seeking to grow its team as it pursues its goal of transforming the treatment landscape for diseases with high unmet needs. The ...
  • Olesia Kramarenko
  • 06.01.2026
Amylyx Pharmaceuticals pushes for novel therapy development
Amylyx Pharmaceuticals has reaffirmed its bold mission to create new therapies that address pressing unmet medical needs. The company emphasizes its commitment to transforming challenges into ...
  • Eugene Komchuk
  • 13.11.2025
Amylyx Pharmaceuticals reveals promising results from Wolfram syndrome trial
Amylyx Pharmaceuticals is set to reveal results from its groundbreaking Phase 2 HELIOS trial for Wolfram syndrome this Saturday. Jamie Timmons, MD, the company's SVP of Medical Affairs, will ...